XXI Wealth LLC’s AbbVie ABBV Stock Holding History

XXI Wealth LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.83M	Buy	7,267 +103	+1%	+$22.2K	0.84%	29
2026 Q1	$1.56M	Sell	7,164 -425	-6%	-$94.3K	0.88%	23
2025 Q4	$1.73M	Buy	+7,589	New	+$1.73M	1.05%	23

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

XXI Wealth LLC's ABBV Position: Q2 2026 in Review

XXI Wealth LLC increased its AbbVie (ABBV) stake by 1.4% in Q2 2026, buying an estimated $22.2K and bringing the position to 7,267 shares worth $1.83M. The position accounts for 0.84% of the portfolio, ranked #29.

XXI Wealth LLC first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

XXI Wealth LLC held 7,267 shares of AbbVie worth $1.83M as of Q2 2026.
XXI Wealth LLC bought 103 AbbVie shares in Q2 2026, an estimated $22.2K.
AbbVie made up 0.84% of XXI Wealth LLC's portfolio in Q2 2026, its #29 holding.
XXI Wealth LLC first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on XXI Wealth LLC's 13F filing for Q2 2026, filed 14 Aug 2026.